Pyrilutamide (KX-826) was among the most anticipated topical anti-androgens in the hair loss pipeline — a selective androgen receptor antagonist designed to block DHT action in the scalp without systemic hormonal effects. Its development path has encountered setbacks that provide useful perspective on how drug development timelines extend beyond analyst projections.
The Drug and Its Mechanism
Pyrilutamide is a nonsteroidal, tissue-selective androgen receptor (AR) antagonist developed by Kinex Pharmaceuticals (China) and licensed to Nuvation Bio for ex-China development. Unlike finasteride and dutasteride — which inhibit the enzyme that produces DHT — pyrilutamide works downstream, blocking DHT from binding to the androgen receptor in follicle cells. This mechanism offers theoretical advantages: no effect on systemic testosterone or DHT levels, meaning the hormonal side effects associated with 5AR inhibitors should not apply.
5-alpha reductase inhibitors (finasteride, dutasteride) → reduce DHT production systemically. Androgen receptor antagonists (pyrilutamide) → block DHT action locally without reducing production. Different mechanism, different side effect profile hypothesis.
Phase II Trial Results (China)
Phase II trials conducted in China produced encouraging results. In a dose-ranging study, pyrilutamide 0.5% topical solution applied once daily showed significant improvement in hair count versus vehicle (placebo) over 24 weeks in men with androgenetic alopecia. The response rates were comparable to or better than topical 2% minoxidil benchmarks, with a notably favorable safety profile — no significant sexual side effects or systemic hormonal changes detected.
Development Setbacks and Current Status
Nuvation Bio's US/international development of pyrilutamide has progressed more slowly than initially projected. As of 2026, the drug remains in Phase III trial stages, with timelines that have extended from initial projections. Regulatory path, manufacturing scale, and enrollment in ex-China trials are factors in the extended timeline.
The China program is further advanced. Kinex has pursued approval through the NMPA (China's FDA equivalent); this does not constitute US or European approval. Patients purchasing compounds marketed as "pyrilutamide" from research chemical vendors or compounding pharmacies are accessing unapproved, unstandardized material outside any clinical oversight.
Where It Fits in the Anti-Androgen Pipeline
Pyrilutamide is the most advanced topical AR antagonist specifically developed for androgenetic alopecia. Clascoterone (Winlevi) — the only FDA-approved topical AR antagonist as of 2026 — was approved for acne, not AGA, though off-label use for hair loss is practiced and has some trial data. Pyrilutamide's AGA-specific development gives it a clearer regulatory path if Phase III data holds.